GHRP-6

What it is

GHRP-6 is a six-amino-acid growth-hormone-releasing peptide. FDA's substance record also calls it Hexapeptide-2, growth hormone releasing hexapeptide, and melanostatine 2. Similar class names do not make it interchangeable with GHRP-2 or Hexarelin.

GHRP-6 is distinct from GHRP-2/pralmorelin, Hexarelin/examorelin, and lysine-substituted GHRP-6 research antagonists. A name does not authenticate form, formulation, route, concentration, purity, sterility, aggregation state, or stability.

Why people care

Reader interest centers on growth hormone, sleep, physique, and recovery claims, while the human record identified here is dominated by small acute endocrine, sleep-EEG, metabolic, and provocative-test studies.

What humans actually show

Small human studies show route- and condition-specific effects on growth hormone, ACTH, cortisol, stage-2 sleep, glucose, and insulin. They do not establish broad sleep, muscle, fat-loss, recovery, or long-term safety benefits, and FDA identifies compounding-specific immunogenicity, cortisol, glucose, and insulin-sensitivity concerns.

• other human — Normal adult male controls in a placebo-controlled nighttime experiment; Route: Repeated intravenous research challenges; Outcome: Sleep EEG plus nocturnal GH, ACTH, and cortisol: GHRP-6 increased GH, ACTH, cortisol, and stage-2 sleep; slow-wave sleep and the other reported sleep-EEG variables did not improve. The seam: The abstract does not state random allocation; Small acute physiology experiment; Stage-2 sleep is not a patient-reported sleep-quality outcome; No chronic sleep or safety assessment; Cannot transfer results to another route or product.
• randomized human — Normal young male controls in placebo comparisons of oral, intranasal, and sublingual conditions; Route: Route-comparison research administration; Outcome: Nocturnal GH, ACTH, cortisol, and sleep EEG: The tested oral condition did not change GH, ACTH, or cortisol; the sublingual condition showed only a GH trend; the intranasal condition increased GH with an ACTH trend. The seam: Small route-specific comparisons; Different study conditions cannot be collapsed; No patient-important clinical outcome; Does not authenticate another product.
• randomized human — Ten healthy subjects enrolled in a double-blind placebo-controlled growth-hormone receptor-blockade experiment; Route: Acute research challenge under fasting and nonfasting conditions; Outcome: Glucose, insulin, free fatty acids, and endocrine responses: Glucose and insulin increased after GHRP-6 in the nonfasting receptor-blockade condition, not across all study conditions; the reported insulin finding was based on a five-participant subgroup. The seam: The subgroup denominator is smaller than total enrollment; Conditional acute experiment; Includes pharmacologic receptor blockade; Does not establish a general chronic metabolic effect; No physique or clinical-benefit outcome.
• other human — Seventeen healthy adults undergoing repeated combined provocative tests; Route: Intravenous GHRH plus GHRP-6 research challenge; Outcome: Reproducibility of peak growth-hormone response: The combined provocative test produced reproducible GH peaks across four test days. The seam: Diagnostic physiology endpoint; Combined endocrine probes; No therapeutic efficacy or long-term safety outcome.

Mechanistic and nonhuman evidence

• animal — Infant rats and cultured rat pituitary cells; Route: Experimental animal administration and in-vitro exposure; Outcome: Growth-hormone release and gene expression: GHRP-6 altered GH release and GH gene expression in the experimental systems. The seam: Animal and cell evidence; Does not establish human benefit; Does not define chronic human safety.
• mechanistic — Ovine and rat pituitary cells; Route: In-vitro exposure; Outcome: Intracellular signaling and growth-hormone release: GHRP-6 and GHRP-2 showed different signaling patterns in the experimental pituitary-cell systems. The seam: Nonhuman cell systems; Mechanistic distinction is not a clinical benefit; Cannot establish human product equivalence.

FDA and U.S. status

FDA currently lists GHRP-6 in category 2 under the 503B interim policy and identifies potential significant safety risks. An exact active-ingredient Drugs@FDA API search returned no GHRP-6 or Hexapeptide-2 match; this draft records that dated result without converting it into a broader approval, legality, or availability conclusion.

Risks and warning limits

• theoretical: FDA says compounded GHRP-6 may pose immunogenicity risk for certain routes because of aggregation and peptide-related impurities.
• human trial: FDA identifies limited safety information and concerns involving cortisol and increased blood glucose through decreased insulin sensitivity; small human studies separately report acute cortisol and condition-specific glucose/insulin changes.
• not characterized: No FDA-approved U.S. GHRP-6 prescribing information was identified, so a complete labeled contraindication, warning, pregnancy, adverse-reaction, and interaction profile is not available from an approved product record.

What remains unknown

• Controlled human effects on sleep quality, strength, lean mass, fat loss, injury recovery, performance, and healthy longevity remain unestablished by the identified record.
• Long-term adverse effects, contraindications, pregnancy effects, immunogenicity by route, rare events, and a complete interaction profile remain incompletely characterized.
• The extent to which conditional acute glucose and insulin findings transfer outside growth-hormone receptor blockade remains unknown.

Product identity and quality limits

• A GHRP-6, Hexapeptide-2, or melanostatine 2 name does not establish sequence, form, concentration, purity, sterility, aggregation state, peptide-impurity profile, or stability.
• A defined research material cannot authenticate an unrelated compounded or online product.

What has been studied together

• Growth hormone-releasing hormone — coadministration studied: Small human studies coadministered GHRH and GHRP-6 to measure acute GH release or provocative-test reproducibility. They do not establish a therapeutic combination, long-term benefit, or broad safety.
• Pegvisomant — coadministration studied: A ten-person experiment studied GHRP-6 during growth-hormone receptor blockade and found condition-specific glucose and insulin changes. That result does not generalize to other medicines or settings.
• Other drugs or peptides — no direct evidence: No adequate clinical-outcome evidence for broader consumer-style combinations was identified in the July 27, 2026 exact-substance search. Missing evidence does not establish compatibility or safety.

What people are hearing

These are claims this profile checks, not established conclusions.

• Claim under review: “A stage-2 sleep change proves GHRP-6 improves deep sleep or sleep quality.”
• Claim under review: “All routes and all products called GHRP-6 have the same effects.”
• Claim under review: “GHRP-6 is interchangeable with GHRP-2 or Hexarelin.”

Questions readers raise

• No reproducible community sample was collected for this profile.

The community-signal layer is not efficacy or safety evidence. Its current limits are:

• No reproducible community sample has been collected for this profile.
• Self-reports would be subject to selection and reporting bias.
• The identity of a product described in a self-report could not be verified.
• Concurrent medicines, behaviors, and health conditions could confound an anecdote.
• Reported outcomes could not be independently verified.
• Anecdotes cannot establish efficacy, safety, approval, product identity, or interaction compatibility.

What would change this answer

• An adequately powered controlled trial measuring patient-important sleep, body-composition, performance, recovery, or other claimed outcomes with complete adverse-event reporting would change the evidence assessment.
• An exact FDA action and prescribing information would change the current U.S. status and labeled-warning boundary.
• Product-level analytical and manufacturing evidence would be required to assess another material; a shared name cannot establish identity.

Sources and records

• WADA — 2026 Prohibited List

• FDA GSRS growth-hormone secretagogue substance records — U.S. Food and Drug Administration
• Certain bulk drug substances for use in compounding that may present significant safety risks — U.S. Food and Drug Administration
• United Pharmacy warning letter — U.S. Food and Drug Administration
• Drugs@FDA API exact active-ingredient search for GHRP-6 — U.S. Food and Drug Administration
• ClinicalTrials.gov intervention search for GHRP-6 — ClinicalTrials.gov
• PubMed Title/Abstract search for GHRP-6 or Hexapeptide-2 — National Library of Medicine
• GHRP-6 stimulates sleep, growth hormone, ACTH and cortisol release in normal man — PubMed
• Effects of GHRP-6 on nocturnal hormones and sleep EEG: role of routes of administration — PubMed
• Growth-hormone receptor blockade unmasks GHRP-6-mediated tissue-specific insulin resistance — PubMed
• Evaluation of reproducibility of the GHRH plus GHRP-6 test of growth hormone reserve — PubMed
• GHRP-6 effects on growth-hormone expression and release in GHRH-deprived infant rats — PubMed
• Effects of GHRP-6 and GHRP-2 on signaling and GH secretion in ovine and rat somatotrophs — PubMed